The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors.
Mitesh J. Borad
No relevant relationships to disclose
Ramesh K. Ramanathan
Consultant or Advisory Role - Halozyme Therapeutics
Research Funding - Halozyme Therapeutics
Alberto Bessudo
No relevant relationships to disclose
Patricia LoRusso
Research Funding - Halozyme Therapeutics
Harold Michael Shepard
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Daniel C. Maneval
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Ping Jiang
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Joy Zhu
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Gregory I Frost
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Jeffrey R. Infante
No relevant relationships to disclose